Financial reports
Current reports
8-K
Entry into a Material Definitive Agreement
4 Nov 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
28 Oct 24
8-K
Allurion Receives Continued Listing Standards Notice from NYSE
5 Sep 24
8-K
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors
4 Sep 24
8-K
Allurion Receives Continued Listing Standards Notice from NYSE
15 Aug 24
8-K
Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update
13 Aug 24
8-K
Other Events
7 Aug 24
8-K
Entry into a Material Definitive Agreement
5 Jul 24
8-K
Allurion Announces Pricing of $20 Million Public Offering and Concurrent Private Placement
1 Jul 24
8-K
Regulation FD Disclosure
25 Jun 24
Registration and prospectus
424B3
Prospectus supplement
5 Nov 24
424B3
Prospectus supplement
5 Nov 24
424B3
Prospectus supplement
5 Nov 24
424B3
Prospectus supplement
29 Oct 24
424B3
Prospectus supplement
29 Oct 24
424B3
Prospectus supplement
29 Oct 24
424B3
Prospectus supplement
29 Oct 24
424B5
Prospectus supplement for primary offering
7 Oct 24
S-1/A
IPO registration (amended)
3 Oct 24
S-1/A
IPO registration (amended)
30 Sep 24
Other
EFFECT
Notice of effectiveness
8 Oct 24
EFFECT
Notice of effectiveness
1 Jul 24
EFFECT
Notice of effectiveness
27 Jun 24
EFFECT
Notice of effectiveness
27 Jun 24
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
27 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
14 Dec 23
CORRESP
Correspondence with SEC
29 Nov 23
Ownership